skip to main content

Potassium Binder RASi Enablement Strategy — ESENeph MCQ

Instant feedback + full explanation. One question, done properly.

ModerateChronic Kidney DiseasePotassium Binder RASi Enablement StrategyESENeph

A 58-year-old woman with CKD G4 (eGFR 22 mL/min/1.73m2) is on ramipril 10 mg daily. Her serum potassium has been persistently 5.6-5.8 mmol/L. She is already on a potassium-restricted diet and has corrected metabolic acidosis with sodium bicarbonate. RASi provides significant renoprotective benefit. What pharmacological strategy can enable continued RASi therapy?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Add patiromer or sodium zirconium cyclosilicate

This is the 'RASi optimisation' paradigm enabled by newer potassium binders. Patiromer and sodium zirconium cyclosilicate (SZC) allow continued RASi therapy in patients who would otherwise require dose reduction or discontinuation due to hyperkalaemia. Multiple trials (AMETHYST-DN, HARMONIZE, AMBER) have demonstrated that concomitant potassium binder therapy enables maintenance of guideline-recommended RASi doses. KDIGO 2024 endorses this strategy: the renoprotective benefit of maintaining full-dose RASi outweighs the cost and burden of adding a potassium binder. Stopping or reducing RASi accelerates CKD progression and proteinuria. Spironolactone would worsen hyperkalaemia.

Reference: KDIGO 2024 – CKD Guideline; Agarwal et al 2019 – AMBER Trial; Bakris et al 2015 – AMETHYST-DN: https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf